 The acute phase will be followed by the 4 months maintenance phase. In the maintenance phase, all medications but lorazepam 4 mg day dose and lamotrigine or sodium valproate will be typed over for initial 4 weeks period. In the last 3 month of the study the lamotrigine subjects will receive only lamotrigine monotherapy. The dose will be adjusted by the study physicians as clinically necessary within the same dose range as in the Phase 1. The sodium valproate dose will be maintained to achieve a therapeutic level of 50-100 mcgml. The subjects will be followed weekly for the first 5 weeks of the study. For the rest of the study the subjects will be followed biweekly 